Fund Overview
The ARK Genomic Revolution ETF, identified by the ticker symbol ARKG, operates within the Health category and is managed by the ARK ETF Trust. This specific fund structure focuses on the genomic revolution sector, distinguishing it from broader market indices or value-oriented portfolios. As of the latest available data, the fund maintains total assets under management of $1.30 billion, a figure that reflects a significant scale for a thematic equity strategy and indicates a substantial level of investor interest in this niche sector. While the specific number of holdings is not publicly disclosed in the current data, the absence of a stated holdings count prevents a direct assessment of diversification breadth through that specific metric alone. The fund charges an expense ratio of 0.8%, which positions it as a higher-cost option compared to the broad market average and many passive index funds that typically charge fractions of a percent. This relatively elevated fee structure is characteristic of active management strategies that attempt to outperform benchmarks through concentrated stock selections rather than passive replication of market weights. Consequently, investors are charged a higher annual fee to access this specific genomic theme, which must be weighed against the potential for outperformance or underperformance relative to lower-cost alternatives.
Performance Analysis
The current annualized yield for the ARK Genomic Revolution ETF is recorded at 0.0%, indicating that the fund does not generate significant income through dividends or distributions for shareholders. For income-seeking investors who rely on regular cash flow from their portfolios, this lack of yield is a defining characteristic that necessitates relying entirely on capital appreciation to generate total returns. On a year-to-date basis, the fund has achieved a return of 3.5%, suggesting that the fund has experienced positive performance in the current fiscal year despite the challenging broader market environment. Looking further back, the fund's three-year average return stands at -4.4%, while the five-year average return is significantly lower at -21.5%. These longer-term figures indicate that the fund has struggled to generate consistent positive returns over multi-year horizons, resulting in a substantial erosion of capital for holders who purchased shares at higher price points during the last five years. Comparing the short-term year-to-date gain of 3.5% against the five-year average loss of -21.5% highlights a sharp divergence between recent market conditions and the fund's historical track record. This disparity suggests that recent market dynamics or specific stock selections within the fund may be driving current gains that do not yet offset the cumulative losses incurred over the longer five-year period. Furthermore, the expense ratio of 0.8% impacts net returns over time by reducing the gross returns generated by the underlying portfolio before they are credited to shareholders. Over a five-year period, these recurring fees compound, effectively widening the gap between the fund's gross performance and the actual returns experienced by investors, which contributes to the negative average returns observed in the long-term metrics.
Price & Risk Profile
The 52-week high for the ARK Genomic Revolution ETF was recorded at $34.39, while the 52-week low was $17.50, defining the price range over the past year. This wide range between the high and low prices indicates substantial price volatility, characteristic of thematic funds that concentrate on specific sectors rather than diversifying across the entire market. The current price of the fund sits roughly in the middle of this 52-week range, having recovered from the yearly low but remaining well below the yearly peak. Without a specific beta value provided in the available data, a precise calculation of the fund's volatility relative to the broader market cannot be performed using the standard beta metric. However, the magnitude of the price swing from $17.50 to $34.39, which represents a wide percentage fluctuation within a single year, inherently suggests a high degree of price sensitivity to market sentiment and sector-specific news. The overall risk profile based on these metrics is defined by significant short-term price instability and the potential for substantial capital loss over longer periods, as evidenced by the negative multi-year returns. Investors engaging with this asset class must be prepared for the possibility of large price swings that can occur within short timeframes, as the fund's performance is not smoothed out by the diversification typically found in broad market index funds. The combination of high volatility and negative long-term averages presents a challenging risk environment where preservation of capital is difficult to achieve without precise timing of entry and exit points.